Summit Therapeutics to Host Utrophin R&D Day 15 June 2016

OXFORD, United Kingdom, June 08, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT) (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit’s management on 15 June 2016 in New York City.

This event is open to analysts, institutional investors and members of the press. For more information, email [email protected].

A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

-END-

You May Also Be Interested In

• Sivers Semiconductors Makes Changes to Senior Leadership Team for Next Phase of Commercial Growth
• Start of Day Message
• Thailand Steps Into the Global Spotlight at TIFF 2026 as TAT Advances Its Film Location and Film Tourism Strategy